about
Ready for a world without antibiotics? The Pensières Antibiotic Resistance Call to Action.New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. ColistinConvulsions in a critically ill patient on hemodialysis: Possible role of low dose colistinCarbapenem-resistant Enterobacteriaceae: a review of treatment and outcomesTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York CityTrough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study.Colistin and polymyxin B: peas in a pod, or chalk and cheese?Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsHigh performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosaUpdated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolColistin: an update on the antibiotic of the 21st century.Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenemsProduct information for parenteral colistin varies substantially across Europe.Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date.Colistin: efficacy and safety in different populations.Therapeutic drug monitoring for colistin therapy in severe multi-resistant Acinetobacter intracerebral abscess: A single case study with high-dose colistin and review of literature.The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients.New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.Preliminary method for direct quantification of colistin methanesulfonate by attenuated total reflectance Fourier transform infrared spectroscopy.Antimicrobial peptides for gram-negative sepsis: a case for the polymyxins.Colistin distribution in the peritoneal fluid of a patient with severe peritonitis.Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.Mechanism-based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing.Latest trends in fungal epidemiology inform treatment choices and stewardship initiatives.Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment
P2860
Q21195823-0B55D2F3-A069-48AF-9C83-ED32AA6B3FF3Q30856181-5B72C171-704D-44B7-ACF5-ABC7037EB89AQ33798554-99DCC47B-9254-425E-B037-6BD2654C6910Q34124176-E0DBFFB3-5DB0-4333-82A3-9C14A5C15FC4Q34320945-53E5CE21-7DB9-4309-AA8B-57CBE0577F81Q34327857-12F280F9-BDC6-482A-8EFB-D69CA274FA40Q34455326-54E71702-4196-47FD-8C3C-ECA1C9D7A2CFQ34955582-7B2D429E-5ED3-4BB9-BA82-638DA658FA1FQ35008357-FE1EB3FF-87AD-4182-B5B8-5772C09EE2D6Q35941403-BE32FF30-5A55-4DBC-A6BF-011E6DD3B51AQ36089663-38502CB9-4DB9-47D5-A613-3CA38D27EA3EQ36240813-B2555E1E-7616-4F31-9C5C-7AC1FCCB94E8Q36543850-4CB51C9D-C2CF-47D1-9E1F-BC1AAD0D4EDFQ36818945-F83992EA-77D8-4C92-9B7D-DD328E75F1D8Q38048852-AA903929-C7B7-4BA5-978B-2C71DCEFA54CQ38101836-2DC97F6D-F932-4747-8A59-8BFC82E54D74Q38126768-5EAE9671-B525-44E0-8141-70D921A97360Q38196299-DB1D1C22-CAF1-45E0-B456-4573F87F6F2FQ38232199-77FF3D44-C179-4FC5-AE82-45FCD1C40BA8Q38514980-4FC41A77-22AE-410C-88BA-BDA402C0F916Q38692023-B10C8623-10F1-49E7-9008-5E26E36B0006Q39236424-AAD00360-C802-497E-9A6D-8C66060086E0Q39333751-18A31716-1729-44FB-830A-98989531E250Q40052709-3AB7897E-0BCE-46BE-8365-5A2475DDDDB4Q41027375-77491EBE-B494-4BE3-B2D3-13BB3ED13050Q41131897-A2A28BA3-40CE-40B9-85D5-BCAD67F4C94BQ42276631-0D79A671-3468-426F-AFE3-AE8B429DC18BQ43219296-A366756E-07A8-4F4A-8D1D-50F8277414E5Q44481718-C31D001F-9D3B-48FD-BC47-D57CD1910E72Q45974680-E95C9939-937A-4D95-BAAC-F09570698F95Q47273930-7DB213AF-34A2-4012-9796-A53C67DA522FQ51118472-BEF1E8D2-3685-48E1-8702-11D33EA15FA2Q51551309-559BC044-4EAE-4E8C-8157-4650BACCE153Q58790968-C2948DC9-9DD6-43D1-BB82-DB8C48861319
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Colistin pharmacokinetics: the fog is lifting.
@en
Colistin pharmacokinetics: the fog is lifting.
@nl
type
label
Colistin pharmacokinetics: the fog is lifting.
@en
Colistin pharmacokinetics: the fog is lifting.
@nl
prefLabel
Colistin pharmacokinetics: the fog is lifting.
@en
Colistin pharmacokinetics: the fog is lifting.
@nl
P50
P1476
Colistin pharmacokinetics: the fog is lifting.
@en
P2093
P356
10.1111/J.1469-0691.2011.03667.X
P577
2011-10-11T00:00:00Z